Subungual oxalate deposits in a patient with secondary hyperoxaluria

Acta Dermato-Venereologica

Volumn 91, Issue 2, 2011, Pages 185-196

  Gregoriou, Stamatis ^a   Kalapothakou, Kanella ^a   Kontochristopoulos, George ^a   Belyayeva, Helena ^a   Chatziolou, Eftihia ^b   Rigopoulos, Dimitris ^a  

^a ANDREAS SYGROS HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

OXALIC ACID; OXALIC ACID DERIVATIVE;

ADULT; CASE REPORT; CHRONIC KIDNEY FAILURE; DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; HYPEROXALURIA; MALE; NAIL DISEASE; PRIORITY JOURNAL; REVIEW; LETTER; PATHOLOGY;

ADULT; HUMANS; HYPEROXALURIA; KIDNEY FAILURE, CHRONIC; MALE; NAIL DISEASES; OXALATES;

EID: 79952402879     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0996     Document Type: Review

References (15)

1. Spiers EM, Sanders DY, Omura EF. Clinical and histologic features of primary oxalosis. J Am Acad Dermatol 1990; 22: 952-956.
2. Rahman N, Hitchcock R. Case report of paediatric oxalate urolithiasis and a review of enteric hyperoxaluria. J Pediatr Urol 2010; 6: 112-116.
3. Ohtake N, Uchiyama H, Furue M, Tamaki K. Secondary cutaneous oxalosis: cutaneous deposition of calcium oxalate dihydrate after long-term haemodialysis. J Am Acad Dermatol 1994; 31: 368-372.
4. Schulze M, Wachter R, Schmeisser A, Fischer R, Strasser RH. Restrictive cardiomyopathy in a patient with primary hyperoxaluria type II. Clin Res Cardiol 2006; 95: 235-240.
5. Bogle MA, Teller CF, Tschen JA, Smith CA, Wang A. Primary hyperoxaluria in a 27-year-old woman. J Am Acad Dermatol 2000; 49: 725-728.
6. Rubenstein MC, Martinelli PT, Bayer-Garner IB, Klebuc MJ, Curry JL, Hsu S. Persistent cutaneous manifestations of hyperoxaluria after combined hepatorenal transplantation. Dermatol Online J 2004; 10: 10.
7. Sikora P, Beck B, Zajaczkowska M, Hoppe B. Plasma oxalate level in paediatric calcium stone formers with or without secondary hyperoxaluria. Urol Res 2009; 37: 101-105.
8. Small KW, Scheinman J, Klintworth GK. A clinicopathological study of ocular involvement in primary hyperoxaluria type I. Br J Ophthalmol 1992; 76: 524-557.
9. Galloway G, Giuliani MJ, Burns DK, Lacomis D. Neuropathy associated with hyperoxaluria: improvement after combined renal and liver transplantations. Brain Pathol 1998; 8: 247-251.
10. Bijarnia RK, Kaur T, Singla SK, Tandon C. Reversal of hyperoxaluria- induced alteration in rat liver by administration of N-acetylcysteine. Drug Chem Toxicol 2007; 30: 229-240.
11. Asselman M, Verhulst A, de Broe ME, Verkoelen CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells. J Am Soc Nephrol 2003; 14: 3155-3166.
12. Jonassen J, Kohjimoto Y, Scheid CR, Schmidt M. Oxalate toxicity in renal cells. Urol Res 2005; 33: 329-339.
13. Khan SR, Glenton PA, Byer KJ. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: Experimental induction of hyperoxaluria by hydroxyl-L-proline. Kidney Int 2006; 70: 914-923.
14. Habibzadegah-Tari P, Byer K. Oxalate induced expression of monocyte chemoattractant protein-1 (MCP-1) in HK-2 cells involves reactive oxygen species. Urol Res 2005; 33: 440-447.
15. Guo C, McMartin KE. The cytotoxicity of oxalate, metabolite of ethylene glycol, is due to calcium oxalate monohydrate formation. Toxicology 2005; 208: 347-355.